A flying Taser-wielding drone has been created by Texas design firm Chaotic Moon.
The device known as Chaotic Unmanned Personal Intercept Drone - Cupid - is capable of delivering 80,000 volts of electricity through a wired dart.
The company's co-founder, Whurley, explained that they wanted to take a concept that has been seen in video games and science fiction films and show that it could be built.
In an experiment not to be repeated at home, Click's Spencer Kelly reports on the demonstration which sees a company intern zapped under controlled conditions.
The device known as Chaotic Unmanned Personal Intercept Drone - Cupid - is capable of delivering 80,000 volts of electricity through a wired dart.
The company's co-founder, Whurley, explained that they wanted to take a concept that has been seen in video games and science fiction films and show that it could be built.
In an experiment not to be repeated at home, Click's Spencer Kelly reports on the demonstration which sees a company intern zapped under controlled conditions.
NEW
DELHI: In what might seem like ironic timing, RanbaxyBSE 2.18 % saw
some good news from the US drug regulator just days before the
announcement of its acquisition on Monday by Sun PharmaceuticalBSE 1.61
% in a $4-billion deal inclusive of debt.
Units of Ranbaxy's R&D centre at Gurgaon and its clinical research centre related to bioequivalence and bioavailabilty at Terapia Ranbaxy, its subsidiary in Romania, were inspected by the USFDA in March and cleared by it, two persons w ..
Units of Ranbaxy's R&D centre at Gurgaon and its clinical research centre related to bioequivalence and bioavailabilty at Terapia Ranbaxy, its subsidiary in Romania, were inspected by the USFDA in March and cleared by it, two persons w ..
NEW
DELHI: In what might seem like ironic timing, RanbaxyBSE 2.18 % saw
some good news from the US drug regulator just days before the
announcement of its acquisition on Monday by Sun PharmaceuticalBSE 1.61
% in a $4-billion deal inclusive of debt.
Units of Ranbaxy's R&D centre at Gurgaon and its clinical research centre related to bioequivalence and bioavailabilty at Terapia Ranbaxy, its subsidiary in Romania, were inspected by the USFDA in March and cleared by it, two persons w ..
Units of Ranbaxy's R&D centre at Gurgaon and its clinical research centre related to bioequivalence and bioavailabilty at Terapia Ranbaxy, its subsidiary in Romania, were inspected by the USFDA in March and cleared by it, two persons w ..
NEW
DELHI: In what might seem like ironic timing, RanbaxyBSE 2.18 % saw
some good news from the US drug regulator just days before the
announcement of its acquisition on Monday by Sun PharmaceuticalBSE 1.61
% in a $4-billion deal inclusive of debt.
Units of Ranbaxy's R&D centre at Gurgaon and its clinical research centre related to bioequivalence and bioavailabilty at Terapia Ranbaxy, its subsidiary in Romania, were inspected by the USFDA in March and cleared by it, two persons w ..
Units of Ranbaxy's R&D centre at Gurgaon and its clinical research centre related to bioequivalence and bioavailabilty at Terapia Ranbaxy, its subsidiary in Romania, were inspected by the USFDA in March and cleared by it, two persons w ..
NEW
DELHI: In what might seem like ironic timing, RanbaxyBSE 2.18 % saw
some good news from the US drug regulator just days before the
announcement of its acquisition on Monday by Sun PharmaceuticalBSE 1.61
% in a $4-billion deal inclusive of debt.
Units of Ranbaxy's R&D centre at Gurgaon and its clinical research centre related to bioequivalence and bioavailabilty at Terapia Ranbaxy, its subsidiary in Romania, were inspected by the USFDA in March and cleared by it, two persons w ..
Units of Ranbaxy's R&D centre at Gurgaon and its clinical research centre related to bioequivalence and bioavailabilty at Terapia Ranbaxy, its subsidiary in Romania, were inspected by the USFDA in March and cleared by it, two persons w ..
NEW
DELHI: In what might seem like ironic timing, RanbaxyBSE 2.18 % saw
some good news from the US drug regulator just days before the
announcement of its acquisition on Monday by Sun PharmaceuticalBSE 1.61
% in a $4-billion deal inclusive of debt.
Units of Ranbaxy's R&D centre at Gurgaon and its clinical research centre related to bioequivalence and bioavailabilty at Terapia Ranbaxy, its subsidiary in Romania, were inspected by the USFDA in March and cleared by it, two persons w ..
Units of Ranbaxy's R&D centre at Gurgaon and its clinical research centre related to bioequivalence and bioavailabilty at Terapia Ranbaxy, its subsidiary in Romania, were inspected by the USFDA in March and cleared by it, two persons w ..
NEW
DELHI: In what might seem like ironic timing, RanbaxyBSE 2.18 % saw
some good news from the US drug regulator just days before the
announcement of its acquisition on Monday by Sun PharmaceuticalBSE 1.61
% in a $4-billion deal inclusive of debt.
Units of Ranbaxy's R&D centre at Gurgaon and its clinical research centre related to bioequivalence and bioavailabilty at Terapia Ranbaxy, its subsidiary in Romania, were inspected by the USFDA in March and cleared by it, two persons w ..
Units of Ranbaxy's R&D centre at Gurgaon and its clinical research centre related to bioequivalence and bioavailabilty at Terapia Ranbaxy, its subsidiary in Romania, were inspected by the USFDA in March and cleared by it, two persons w ..
Read more at:
http://economictimes.indiatimes.com/articleshow/33499011.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
http://economictimes.indiatimes.com/articleshow/33499011.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
NEW
DELHI: In what might seem like ironic timing, RanbaxyBSE 2.18 % saw
some good news from the US drug regulator just days before the
announcement of its acquisition on Monday by Sun PharmaceuticalBSE 1.61
% in a $4-billion deal inclusive of debt.
Units of Ranbaxy's R&D centre at Gurgaon and its clinical research centre related to bioequivalence and bioavailabilty at Terapia Ranbaxy, its subsidiary in Romania, were inspected by the USFDA in March and cleared by it, two persons w ..
Units of Ranbaxy's R&D centre at Gurgaon and its clinical research centre related to bioequivalence and bioavailabilty at Terapia Ranbaxy, its subsidiary in Romania, were inspected by the USFDA in March and cleared by it, two persons w ..
0 comments:
Post a Comment